eClinical Technology and Industy News

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

Excerpt from the Press Release:

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, today announced RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium). RenovoTAMP is a unique therapy platform designed for targeted intra-arterial (IA) delivery of chemotherapy directly to tumors. This symposium was the 30th annual AIMsymposium and is being held November 14-17, 2022 at the New York Hilton.

Presentations included:

  • Dr. Ripal Gandhi, Professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, presented “Advances in the Management of Pancreatic Cancer,” and provided an overview of the clinical challenges of the standard-of-care treatment available to locally advanced pancreatic cancer (LAPC) patients. Systemic intravenous (IV) chemotherapy is considered the standard of care for LAPC and is often associated with debilitating side effects and may be ineffective in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy.

    Dr. Gandhi highlighted the RenovoTAMP therapy platform’s potential as a targeted oncology option for LAPC patients. The presentation reviewed RenovoRx’s RR1 Phase I/II and RR2 Observational Registry studies and RenovoTAMP’s potential to increase chemotherapy delivery directly to the tumor to increase survival and reduce systemic toxicity. Dr. Gandhi also presented the mission and protocol behind the TIGeR-PaC study.

    The Phase III TIGeR-PaC study is evaluating RenovoRx’s first product candidate, RenovoGem™, to treat LAPC through RenovoTAMP’s intra-arterial delivery of gemcitabine, an FDA-approved chemotherapy. Study goals include the extension of patient survival, reduction of side effects associated with systemic chemotherapy, and improved quality of life for pancreatic cancer patients.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives